Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 17/20 | 0.71 |
| ▸ | RAF1 | P04049 | 10/20 | 0.71 |
| ▸ | MAP3K8 | P41279 | 3/20 | 0.59 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.59 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.53 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4775895 | 0.91 | MAP2K1 (0.70) | MAP2K1RAF1MAP3K8MAPK13SRC | |
| SCHEMBL4766938 | 0.90 | MAP2K1 (0.64) | MAP2K1RAF1MAP3K8EGFRERBB2 | |
| SCHEMBL4775833 | 0.90 | MAP2K1 (0.60) | MAP2K1RAF1MAP3K8EGFRERBB2 | |
| SCHEMBL5110365 | 0.87 | MAP2K1 (0.65) | MAP2K1RAF1MAP3K8EGFRERBB2 | |
| SCHEMBL5253113 | 0.85 | MAP2K1 (0.82) | MAP2K1RAF1MAP3K8MAPK13SRC | |
| SCHEMBL4776688 | 0.85 | EGFR (0.67) | MAP2K1RAF1MAP3K8SRCEGFR | |
| SCHEMBL5114679 | 0.84 | MAP2K1 (0.59) | MAP2K1RAF1MAP3K8MAPK13SRC | |
| SCHEMBL4777269 | 0.84 | MAP2K1 (0.67) | MAP2K1RAF1MAP3K8MAPK13SRC | |
| SCHEMBL27709790 | 0.84 | MAP2K1 (0.54) | MAP2K1RAF1SRCEGFRERBB2 | |
| SCHEMBL27707570 | 0.83 | MAP2K1 (1.00) | MAP2K1RAF1MAP3K8MAPK13SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6355636-B1 | ENZYME INHIBITORS | AMERICAN CYANAMID COMPANY | 2002-03-12 | — | — | US | claimed |
| US-7432279-B2 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1881981-A1 | 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | Wyeth (US) | 2008-01-30 | — | — | EP | disclosed |
| US-20060276498-A1 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124944-A1 | 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
| US-6548496-B2 | Anticancer agents | AMERICAN CYANAMID COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-20020165229-A1 | Substituted 3-cyano-[1.7], [1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases | AMERICAN CYANAMID COMPANY | 2002-11-07 | — | — | US | disclosed |
| US-6355636-B1 | ENZYME INHIBITORS | AMERICAN CYANAMID COMPANY | 2002-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276498-A1 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CNKSR1, DTYMK | MAP2K1 416/4885RAF1 160/4885MAP3K8 99/4885 |
| US-20020165229-A1 | Substituted 3-cyano-[1.7], [1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases | ABL1, ROS1, ALK | MAP2K1 175/4885RAF1 111/4885MAP3K8 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.